{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670320116685312.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1056/nejmp1006304"}},{"identifier":{"@type":"URI","@value":"http://www.nejm.org/doi/pdf/10.1056/NEJMp1006304"}}],"dc:title":[{"@value":"The Path to Personalized Medicine"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383670320116685312","@type":"Researcher","foaf:name":[{"@value":"Margaret A. Hamburg"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320116685313","@type":"Researcher","foaf:name":[{"@value":"Francis S. Collins"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00284793"},{"@type":"EISSN","@value":"15334406"}],"prism:publicationName":[{"@value":"New England Journal of Medicine"}],"dc:publisher":[{"@value":"Massachusetts Medical Society"}],"prism:publicationDate":"2010-07-22","prism:volume":"363","prism:number":"4","prism:startingPage":"301","prism:endingPage":"304"},"reviewed":"false","url":[{"@id":"http://www.nejm.org/doi/pdf/10.1056/NEJMp1006304"}],"createdAt":"2010-06-15","modifiedAt":"2016-11-02","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050294113707912064","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Identification of the ultrahigh-risk subgroup in neuroblastoma cases through DNA methylation analysis and its treatment exploiting cancer metabolism"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004232058567808","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Biomanufacturing"}]},{"@id":"https://cir.nii.ac.jp/crid/1360025431112162944","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Understanding the Pathophysiology of Mental Diseases and Early Diagnosis Thanks to Electrophysiological Tools: Some Insights and Empirical Facts"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848662537648256","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A selected reaction monitoring mass spectrometric assessment of biomarker candidates diagnosing large-cell neuroendocrine lung carcinoma by the scaling method using endogenous references"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861707134478976","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The oncogene-dependent resistance to reprogramming unveils cancer therapeutic targets"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204451257600","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Limitation of the evidenced based approach in the era of recently developed antithrombotic agents"},{"@value":"抗血小板・抗凝固薬のエビデンスとその問題点"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204476516608","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Overview of the BioBank Japan Project: Study design and profile"},{"@value":"Overview of the BioBank Japan project: study design and profiles"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205105141888","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Dabigatran in Clinical Practice for Atrial Fibrillation With Special Reference to Activated Partial Thromboplastin Time"},{"@value":"Monitoring of the Effects of New-Generation Oral Anticoagulants"},{"@value":"Monitoring of the effects of new-generation oral anticoagulants – what does it mean?"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205230807168","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Pharmacogenomics and Personalized Medicine"},{"@language":"ja","@value":"ファーマコゲノミクス（PGx）とオーダーメイド医療"},{"@language":"ja-Kana","@value":"ファーマコゲノミクス(PGx)ト オーダーメイド イリョウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390025419436261632","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"腎機能に基づく<sup>99m</sup>Tc-MDP投与量最適化："},{"@language":"en","@value":"Optimization of <sup>99m</sup>Tc-MDP Dose Based on Renal Function:"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679617201664","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Proposal for the Japan society of Drug Delivery System"},{"@language":"ja","@value":"これからのDDS学会への提言（行政の立場から）"},{"@language":"ja-Kana","@value":"コレカラ ノ DDS ガッカイ エ ノ テイゲン(ギョウセイ ノ タチバ カラ)"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1056/nejmp1006304"},{"@type":"CROSSREF","@value":"10.1177/15500594241227485_references_DOI_IiyqrJ0ZYNcpFwmMjYtx4VByHWT"},{"@type":"CROSSREF","@value":"10.2974/kmj.75.351_references_DOI_IiyqrJ0ZYNcpFwmMjYtx4VByHWT"},{"@type":"CROSSREF","@value":"10.1016/j.je.2016.12.005_references_DOI_IiyqrJ0ZYNcpFwmMjYtx4VByHWT"},{"@type":"CROSSREF","@value":"10.1272/manms.8.9_references_DOI_IiyqrJ0ZYNcpFwmMjYtx4VByHWT"},{"@type":"CROSSREF","@value":"10.2491/jjsth.23.3_references_DOI_IiyqrJ0ZYNcpFwmMjYtx4VByHWT"},{"@type":"CROSSREF","@value":"10.2745/dds.29.73_references_DOI_IiyqrJ0ZYNcpFwmMjYtx4VByHWT"},{"@type":"CROSSREF","@value":"10.1016/j.cirp.2013.05.001_references_DOI_IiyqrJ0ZYNcpFwmMjYtx4VByHWT"},{"@type":"CROSSREF","@value":"10.1253/circj.cj-12-0145_references_DOI_IiyqrJ0ZYNcpFwmMjYtx4VByHWT"},{"@type":"CROSSREF","@value":"10.1371/journal.pone.0176219_references_DOI_IiyqrJ0ZYNcpFwmMjYtx4VByHWT"},{"@type":"CROSSREF","@value":"10.1038/s41388-022-02489-2_references_DOI_IiyqrJ0ZYNcpFwmMjYtx4VByHWT"},{"@type":"CROSSREF","@value":"10.1016/j.celrep.2022.110721_references_DOI_IiyqrJ0ZYNcpFwmMjYtx4VByHWT"}]}